Table 1

Baseline characteristics

n=571
mean (SD) or n (%)
Age, years55.7 (12.9)
Female gender434 (76.0%)
Disease duration, years6.5 (8.0)
Education, years12.6 (3.8)
Number of comorbidities1.2 (1.3)
Rheumatoid factor positivity370 (68.0%)
Anti-CCP positivity388 (69.3%)
RF and/or anti-CCP positivity431 (77.7%)
DAS44 (0–10)3.8 (1.0)
DAS28-ESR (0–10)5.2 (1.2)
CDAI (0–76)26.9 (11.6)
SDAI (0–86)28.5 (12.4)
Patient global (0–10)5.7 (2.3)
HAQ (0–3)1.1 (0.7)
SJC (0–44)8.4 (6.1)
TJC (0–53)13.6 (9.1)
ESR (mm/h)28.7 (22.2)
CRP (mg/dL)1.5 (2.3)
Number of prior DMARDs0.9 (1.1)
DMARD naïve274 (48.0%)
Smoking status
 Never smoker282 (49.4%)
 Current smoker161 (28.2%)
 Ex-smoker128 (22.4%)
Treatment csDMARD/TNFi started at baseline
 Both196 (34.6%)
 csDMARD only334 (58.9%)
 TNFi only36 (6.3%)
 None1 (0.2%)
Treatment with oral corticosteroids started at baseline255 (45%)
  • anti-CCP, anti-citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; DAS44, 44-joint disease activity score; DAS28-ESR, 28-joint disease activity score (with ESR); DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SDAI, Simple Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.